Cite
HARVARD Citation
Yap, T. et al. (n.d.). 318 Olaparib plus pembrolizumab in patients with previously treated advanced solid tumors with homologous recombination repair mutation and/or homologous recombination repair deficiency: KEYLYNK-007. Journal for immunotherapy of cancer. pp. A195-A196. [Online].